Healthcare and Life Sciences Executive Recruitment

Healthcare and Life Sciences Executive Recruitment

Exec Capital provides senior executive search for UK healthcare and life sciences firms across the full sub-sector range — pharmaceuticals, biotech, medical devices, diagnostics, digital health, clinical research organisations, and healthcare services. Senior hiring in this sector is shaped by substantial regulatory complexity, clinical and scientific depth requirements, long product-development cycles, and complex stakeholder relationships across regulators, payers, clinicians and patients. The successful appointments are those calibrated to the specific sub-sector context from the start, with substantive understanding of the regulatory landscape (MHRA, FDA, EMA, NICE, CQC, HRA) built into the brief and assessment.

Our practice covers UK senior appointments across CEO, CFO, COO, CMO (Chief Medical Officer), Chief Scientific Officer, Chief Commercial Officer, Head of Regulatory Affairs and broader senior leadership at pharma firms, growth-stage biotech, listed and private medical devices businesses, digital health scale-ups, diagnostics firms, CROs and contract development organisations, and healthcare services groups. Every search is run by our specialist team, with Adrian Lawrence FCA overseeing each mandate from brief to appointment.

That includes the parts of the sector that rarely get a dedicated search partner: independent hospital and clinic groups, domiciliary and residential care operators, specialist care providers, medtech manufacturers, contract services businesses selling into pharma and biotech, and healthtech companies building software for clinicians, patients and commissioners. Whether you need a healthcare CEO to take a care group through its next phase of growth, a finance leader for a biotech approaching a funding round, or an interim operator to stabilise a service after a difficult inspection, the search starts from the same place — a clear understanding of the sub-sector, the regulator and the stage of the business.

Healthcare and life sciences is the sector where sub-sector specifics matter most for senior search. A pharma CEO and a digital health CEO operate in fundamentally different commercial worlds — different stakeholder bases, different regulatory environments, different time horizons, different capital structures. The pattern that recurs is firms briefing senior search at the sector level without working through the sub-sector specifics, with the result that shortlists include candidates whose credentials don’t transfer cleanly. The strongest searches start with substantive sub-sector framing.

That is why we run healthcare and life sciences senior searches with sub-sector specifics worked through at the front of the brief. Strong candidates evaluate firms carefully — the regulatory posture, the clinical or scientific dimensions of the strategy, the realistic commercial trajectory, and any matters in the firm’s recent history that bear on the role. A search that cannot answer those questions credibly loses the best people early.

Sub-sectors we cover

The healthcare and life sciences sector divides into seven sub-sectors, each with substantively different commercial dynamics, regulatory environments and candidate pools. Our practice covers senior appointments across all seven.

Pharmaceuticals. Established pharma, mid-market UK pharma, and the emerging-pharma segment. Senior hiring typically emphasises substantive scientific or clinical credentials alongside commercial track record.

Biotech. Earlier-stage drug discovery and development firms, often venture-backed or recently listed. Senior team quality is one of the dominant value drivers, with capital markets fluency frequently required for senior commercial and finance leadership.

Medical devices. Diagnostics, surgical instruments, monitoring equipment, implantable devices. A different regulatory pathway from pharma (the UK Medical Devices Regulations 2002 and UKCA or CE marking in Great Britain, the EU MDR in Europe, and FDA 510(k) and PMA in the US), shorter product cycles, and different commercial dynamics around hospital procurement and clinician decision-making.

Digital health. Software, AI, telemedicine, digital therapeutics, health data platforms. One of the fastest-growing parts of the UK sector over the past decade. Senior hiring blends technology and digital credentials with healthcare domain expertise.

Diagnostics. Laboratory testing, imaging, in vitro diagnostics, genetic testing. Both clinical-laboratory firms and diagnostic device manufacturers.

Clinical research organisations (CROs) and contract development. Service providers to pharma and biotech for clinical trial conduct, regulatory work, and contract development manufacturing.

Healthcare services. Care home operators, private hospital groups, primary care groups, occupational health providers, and NHS-adjacent service businesses.

In practice, the boundaries blur. A diagnostics business may run CQC-registered clinics and manufacture devices; a healthtech company may sell software that is itself regulated as a medical device; a care group may be building its own digital platform. Part of the brief work is mapping which of these worlds the business genuinely sits in, because that determines which regulatory experience the leader must bring on day one and which they can learn in post.

Independent healthcare and care

Independent healthcare and social care is where much of our work in healthcare services sits. Boards here are hiring leaders who can run a regulated, people-intensive operation on tight margins: managing workforce supply and agency spend, keeping quality and inspection outcomes on track across multiple locations, dealing with local authority and NHS commissioners as customers, and often working to a private equity or family owner’s value-creation plan at the same time. The best candidates have run multi-site regulated services, can talk credibly about governance of clinical and care quality, and understand that a poor inspection outcome is a commercial event, not only a compliance one.

Medtech, biotech and pharma services

Medtech manufacturers, biotech companies and the service businesses around them — CROs, contract development and manufacturing organisations, regulatory consultancies, specialist logistics — recruit leaders against milestones. The milestone might be a regulatory submission, a first-in-human study, a manufacturing scale-up, a commercial launch or a funding round. Leaders need to show they have delivered against comparable milestones, managed the cash runway that goes with them, and worked alongside quality and regulatory functions rather than around them.

Healthtech

Healthtech businesses sit between software and healthcare. Their leaders must understand long NHS and provider sales cycles, information governance and clinical safety, and in some cases the point at which a software product becomes a regulated medical device. Candidates who have only sold software into other sectors often underestimate this; candidates who have only worked inside the NHS can find the pace of a venture-backed company hard. The search is usually for the rare leader who has done both.

Senior roles we recruit

Our healthcare and life sciences practice covers senior appointments across the executive team and the boardroom.

Chief Executive Officer. Substantive sector experience plus the standard CEO dimensions — commercial leadership, board engagement, capital markets familiarity. Pharma and biotech CEOs typically come from senior commercial roles within the sector; digital health CEOs may come from technology backgrounds with healthcare domain expertise.

Chief Financial Officer. Healthcare and life sciences CFOs typically require sector-specific capital markets experience (where listed), regulatory financial reporting awareness, and (for pharma and biotech) experience of milestone-driven capital structures. Our CFO recruitment practice works cross-portfolio with our sister firm FD Capital where the CFO seat is the primary specialism.

Chief Operating Officer. Particularly central in mid-market pharma and biotech firms approaching commercial scaling, and at healthcare services groups with substantial operational complexity. For care and hospital groups, COO recruitment is often the hire that decides whether growth by acquisition or new sites is delivered safely.

Chief Medical Officer. The senior clinical leader, typically a qualified medical doctor with substantive clinical and pharmaceutical or device development experience. Distinct from the corporate Chief Marketing Officer.

Chief Scientific Officer. Often appointed alongside or in place of a clinical CMO, particularly in pre-commercial biotech and emerging pharma firms.

Chief Commercial Officer. Particularly central in established pharma, biotech approaching launch, and medical devices firms. The CCO leads market access, payer relationships, and commercial strategy. Where the business needs a hands-on commercial lead below board level, we also run commercial director recruitment.

Head of Regulatory Affairs. Senior regulatory leader with substantive prior regulatory authority engagement. The role is the firm’s senior interface with MHRA, FDA, EMA and equivalent bodies.

Non-Executive Directors and Chairs. Independent NEDs with substantive sector experience, including audit committee chairs, risk committee chairs, and Chairs of pre-IPO and listed life sciences firms. Our dedicated healthcare and life sciences NED recruitment page covers board appointments in more depth.

Below the C-suite, we also recruit the operational leaders that healthcare services businesses depend on: regional operations directors for care and clinic groups, quality and clinical governance directors, and senior people leaders responsible for workforce planning. Those roles often matter as much to inspection outcomes and margins as the executive team itself.

Which leader does a healthcare or life sciences business need?

Boards often know something is wrong before they know which hire will fix it. The table below maps common situations to the leader who usually owns the answer. It is a starting point for the brief, not a rule: a small business may combine two of these roles, and a larger one may need both.

If the table points to more than one answer, that is normal. Many of the briefs we take start as “we need a CEO” and end as “we need a stronger COO and a fractional CFO, and the founder stays as CEO”. Working that out before the search begins saves months.

How we work

We run healthcare and life sciences searches on a retained basis, with engagement running through to the candidate’s first day in role. The brief phase covers sub-sector specifics, regulatory dimensions, and the candidate pool framing before formal mandate begins. Market mapping draws on the substantive sector network plus targeted approaches to specialists at peer firms. Assessment combines structured competency interviews with case-style discussion of the firm’s specific commercial and regulatory situation.

Our specialist team runs each search — from the brief, through market mapping and engagement, to the offer negotiation and the onboarding work that follows — with Adrian Lawrence FCA overseeing each mandate. You deal with the same people throughout, and they know your business, your board and your sub-sector.

How a healthcare executive search works, step by step

Every search follows the same six stages. We agree the timetable with you at briefing, because it depends on the role, the format, notice periods in the candidate pool and any regulatory steps that apply.

Permanent, interim or fractional: choosing the format

Not every healthcare or life sciences leadership gap needs a permanent hire. A biotech between funding rounds may need senior finance capacity two days a week; a care group facing an urgent quality problem may need a full-time interim operator in post as soon as possible; a listed medtech business replacing its CEO will usually want a permanent appointment and a full search. The right format depends on how long the need lasts, how much of a full-time role there genuinely is, and how much risk the board can carry while it waits.

For urgent gaps we run interim executive recruitment, including interim CEOs and interim CFOs who can step in while a permanent search runs. For earlier-stage businesses, a fractional C-suite gives access to experienced leaders for a few days a week. Our guide to scaling healthcare start-ups with fractional executives looks at that model in detail, and our fractional, interim and permanent comparison sets out the trade-offs across sectors.

Regulatory context that shapes senior hires

Regulation is the single biggest difference between a healthcare search and a search in most other sectors. It changes what the leader must already know, which checks the employer must make, and sometimes whether the appointee can start work before a regulator has acted. The points below are the ones that most often affect our briefs. They are a summary for hiring purposes, not legal advice, and you should check the current position with the regulator or your advisers before relying on them.

CQC registration, the Registered Manager and fit and proper directors

In England, providers of regulated health and social care activities register with the Care Quality Commission. Two requirements matter directly for leadership hiring. First, the CQC’s registered manager guidance says a person in charge of the day-to-day running of regulated activities at a location must register as a manager, and cannot manage those activities until CQC confirms the registration. Applicants need a recent enhanced DBS check, relevant qualifications, proven management experience and a full work history. For a care or clinic group, that means operational leadership hires below the executive team often carry their own registration process, which needs to be built into the start date.

Second, under the fit and proper person requirement for directors (Regulation 5), registered providers must assure themselves that their directors, or people in equivalent roles, are fit and proper. CQC is clear that it does not certify individuals; the responsibility sits with the provider’s own recruitment and checking. In practice, executive and board appointments at CQC-registered providers need documented checks on character, qualifications, experience and any history of serious misconduct or mismanagement. We build those checks into the offer stage so the board has the evidence it needs.

MHRA and medical device obligations

For medtech and diagnostics businesses, the Medicines and Healthcare products Regulatory Agency is the UK regulator. New post-market surveillance requirements for medical devices placed on the Great Britain market came into force on 16 June 2025, applying to UKCA- and CE-marked devices. Manufacturers must monitor real-world performance more closely, meet a 15-day deadline for reporting serious incidents (down from 30), and submit field safety notices to the MHRA for review before issuing them. The MHRA’s wider future regime for devices is being introduced in stages. For senior hiring, this raises the bar for regulatory, quality and operations leaders, and boards increasingly want a CEO or COO who has run a business under active post-market obligations rather than only pre-market development.

NHS structural change

Many independent healthcare, healthtech and services businesses sell to the NHS, so NHS structures affect their commercial leadership. The government’s Health Bill, published in May 2026, would abolish NHS England and transfer its functions into the Department of Health and Social Care. As at November 2026 the Bill is still going through Parliament, so the final shape and timing are not settled. For hiring, the practical point is that commercial and market access leaders selling into the NHS need to show they can adapt as commissioning and procurement routes change, and should be able to talk credibly about how their business would respond.

Clinical research, medicines and assessment bodies

Biotech, pharma and CRO leaders also work with the Health Research Authority on research approvals, with NICE on health technology assessment, and with the MHRA on clinical trials and medicines licensing, alongside the FDA and EMA where they sell internationally. The depth of that experience a leader needs depends on the role: essential for a Head of Regulatory Affairs or Chief Medical Officer, important for a CEO or CCO, and useful context for a CFO who must model the cost and timing of regulatory milestones.

What a new healthcare executive typically delivers in the first 90 days

The first three months set the tone for any senior appointment. In healthcare and life sciences they are also when a new leader learns where the regulatory and clinical risks really sit. A well-briefed appointee will usually work through four things.

• Days 1–30: listen and assess. Meet the board, investors, clinical and quality leads, key customers and commissioners. Review recent inspection reports, regulatory correspondence, incident logs, the cash position and the pipeline or service plan.
• Days 31–60: confirm priorities. Agree with the board the two or three issues that matter most — a funding milestone, an inspection action plan, a launch, a margin problem — and the measures that will show progress.
• Days 61–90: act and build the team. Make early changes where risk is clear, start any senior hires the plan needs, and put regular reporting to the board in place.
• Throughout: protect patients and compliance. No commercial plan survives a serious safety or regulatory failure. Strong leaders make clear early that quality governance is part of their own job, not a function they delegate and forget.

Interim and fractional leaders compress this. An interim brought in after a poor inspection may be expected to have an action plan agreed with the board within the first weeks; a fractional CFO may spend the first month rebuilding the forecast before anything else. We agree the expected outputs with you at briefing so the shortlist is assessed against them. Our executive onboarding guide covers how boards can support a new leader through this period.

Why Exec Capital for healthcare and life sciences

Three dimensions distinguish our healthcare and life sciences practice.

Sub-sector specificity worked through at the brief. We don’t approach healthcare as a single market. The pharma versus biotech distinction, the medical devices versus digital health distinction, the diagnostics versus CRO distinction — these all matter substantively to which candidates fit the role. The brief work at the front of every search calibrates the search to the specific sub-sector.

Substantive regulatory understanding. Strong candidates at this level expect senior search firms to understand the regulatory landscape — MHRA, FDA, EMA pathways; NICE health technology assessment; CQC frameworks for healthcare services; HRA governance for clinical research. Search firms that present generically lose strong candidates fast.

Senior oversight throughout. Our specialist team runs each search, with Adrian Lawrence FCA, ICAEW Fellow and founder of Exec Capital, overseeing every senior healthcare and life sciences mandate. As a chartered accountant and former listed-company finance director, Adrian brings a board-level view of the commercial and financial side of each appointment, and the relationship with the chair and CEO stays with senior people rather than being handed down.

We also work across formats. Because we place permanent, interim and fractional leaders, we can give a straight view on which one fits your situation rather than steering every brief towards a permanent fee, and we can cover an urgent gap with an interim while a permanent search runs.

Common mistakes in healthcare leadership hiring

The same handful of problems explain most failed senior appointments in this sector. Avoiding them is mostly a matter of doing the thinking before the search starts.

• Briefing at sector level. “A healthcare CEO” is not a brief. A care operator, a diagnostics manufacturer and a healthtech platform need different people, and a shortlist drawn from all three will waste the board’s time.
• Hiring for the last stage of the business. A leader who was excellent through development may not be the right one for launch, and a leader who scaled a provider through acquisitions may not suit a period of consolidation. Brief for the next three to five years, not the last three.
• Leaving regulatory steps until the offer. Registered Manager applications, fit and proper checks and DBS checks all take time. Building them into the timetable at the start avoids a signed candidate who cannot yet do the job.
• Ignoring the clinical relationship. In provider businesses especially, a CEO or COO who cannot win the trust of clinicians and care staff will struggle however strong their commercial record. Include senior clinical voices in the interview process.
• Defaulting to a permanent hire. If the need is a funding round, a turnaround or an inspection recovery, an interim or fractional leader may deliver the outcome faster and at lower risk, leaving the permanent decision until the business is clearer about what it needs.

Engagement and fees

How we charge depends on the format of the hire. We set out the terms in writing before any work begins, and there are no hidden costs.

• Permanent executive search. Senior permanent healthcare and life sciences appointments are run on a retained basis: a fee linked to the role’s first-year package, paid in stages through the search. Retained search means a committed team, a full market map and confidential direct approaches, which is what C-suite and board roles in a specialist sector need.
• Contingent search. For some roles below the executive team we can work on a contingent basis, with the fee payable only on appointment. We will tell you honestly at briefing which approach suits the role.
• Interim and fractional. Interim and fractional leaders are engaged on a day rate agreed before they start, usually invoiced monthly. The rate depends on the role, the seniority required and the days per week.
• What is included. Briefing, market mapping, direct approaches, candidate assessment, shortlist reports, interview management, referencing and suitability checks, offer negotiation and follow-up after the appointee starts.

Our guide to retained versus contingent executive search explains the difference in more detail.

Compensation and Package Structure

Packages in healthcare and life sciences vary more by ownership and stage than by job title. A CEO of a venture-backed biotech may take a modest base salary with a significant equity stake tied to clinical or financing milestones; a CEO of a private equity-backed care group will usually have a market-rate salary, an annual bonus linked to earnings and quality measures, and a sweet equity or management incentive plan; a listed medtech CEO’s package will follow the company’s shareholder-approved remuneration policy. Clinical leaders such as Chief Medical Officers may also want to keep some clinical practice, which affects working pattern and package design.

We discuss package range at briefing and test it against the market during the search, so there are no surprises at offer stage. For broader context, see our C-suite salary guide.

Who we place

Our healthcare and life sciences clients are usually one of the following:

• Independent healthcare providers: private hospital and clinic groups, diagnostic and imaging centres, dental and specialist practice groups.
• Care operators: residential, nursing, domiciliary and specialist care businesses, from single-region operators to national groups.
• Medtech and diagnostics companies: device and diagnostics manufacturers from development stage to established businesses selling internationally.
• Biotech and pharma services: drug discovery and development companies, CROs, contract development and manufacturing businesses, and specialist consultancies serving the sector.
• Healthtech: software, data, AI and digital therapeutics businesses selling to the NHS, private providers, insurers and patients.
• Investors: private equity and venture capital firms hiring into portfolio companies in the sector, and boards preparing for investment, sale or listing. Our private equity executive search team works closely with sector investors.

The people we place are typically experienced executives who have led in one of these sub-sectors, and sometimes leaders from adjacent sectors — technology, consumer services, logistics, financial services — where the board has decided that a transferable skill set outweighs direct sector experience and the regulatory gap can be covered elsewhere in the team.

For candidates

If you are a healthcare or life sciences executive looking for your next permanent, interim or fractional role, please register with us and keep an eye on our current opportunities. Many of our searches are confidential and are never advertised, so registering is the best way to be considered.

Further reading

For our substantive guide to UK healthcare and life sciences senior hiring covering all seven sub-sectors, the senior team typically required, and the candidate pool, see our Healthcare and Life Sciences Executive Hiring Guide.

For role-specific senior hiring guides, see our CEO hiring guide, COO hiring guide, Chief Commercial Officer hiring guide, and the rest in our Knowledge Centre. For senior CFO appointments at healthcare and life sciences firms specifically, see our sister firm FD Capital.

For UK healthcare and life sciences regulatory frameworks referenced in our work, see the MHRA, NICE, the CQC, and the HRA. For UK life sciences industry context, see the ABPI and the BIA.

Frequently asked questions

What is healthcare executive recruitment?

Healthcare executive recruitment is the search for senior leaders — CEOs, CFOs, COOs, medical, commercial and regulatory directors, and non-executive directors — for healthcare providers, care operators, medtech, biotech, pharma services and healthtech businesses. It differs from general executive search because candidates must be assessed on regulatory, clinical and sector experience as well as leadership and commercial track record.

How is life sciences executive search different from other sectors?

Life sciences businesses are built around long development cycles, regulatory milestones and specialist funding. Leaders need experience of the relevant approval route — medicines, devices or diagnostics — and of raising or managing capital against milestones. The candidate pool is smaller and more specialised, so direct, confidential approaches matter more than advertising.

Do you recruit healthcare CEOs from outside the sector?

Sometimes. For a care or clinic group, a leader with strong multi-site operating experience from another regulated, people-heavy sector can work well if the board has clinical and quality leadership around them. For biotech or medtech, direct sector experience is usually essential. We discuss the trade-off openly at briefing.

Do you handle medtech and biotech executive recruitment?

Yes. We recruit CEOs, CFOs, COOs, Chief Scientific and Chief Medical Officers, commercial leaders, and regulatory and quality heads for medtech, diagnostics and biotech businesses, from development stage through to companies selling internationally.

Can you provide an interim or fractional healthcare executive?

Yes. Interim executives work full-time for a fixed period, for example to stabilise a service, cover a departure or lead a transaction. Fractional executives work one to three days a week on an ongoing basis, which suits early-stage healthtech, biotech and smaller providers. Both are engaged on a day rate.

Does a new executive need CQC approval?

CQC does not approve executive directors individually, but registered providers must satisfy themselves that directors meet the fit and proper person requirement. Separately, the person in charge of the day-to-day running of regulated activities at a location must register with CQC as a Registered Manager before managing those activities. We factor both into the timetable.

How long does a healthcare executive search take?

It depends on the role, the format, candidates’ notice periods and any registration steps. Interim and fractional appointments are usually much quicker than permanent searches. We agree a realistic timetable with you at briefing and report progress against it.

How do you charge for healthcare and life sciences searches?

Permanent executive appointments are usually retained, with a fee linked to the first-year package and paid in stages. Some roles below executive level can be contingent. Interim and fractional placements are charged on an agreed day rate. Terms are confirmed in writing before the search begins.

Do you recruit non-executive directors for healthcare boards?

Yes. We recruit independent NEDs, committee chairs and chairs for healthcare and life sciences boards, including clinically experienced NEDs, audit committee chairs and chairs preparing businesses for investment, sale or listing.

Is the search confidential?

Yes. Many healthcare leadership changes are sensitive, particularly where an incumbent is still in post, a transaction is planned or a regulatory issue is being addressed. We approach candidates without naming the client until both sides are ready.